SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-028159
Filing Date
2020-06-03
Accepted
2020-06-03 09:44:41
Documents
8
Period of Report
2020-06-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20200601.htm 8-K 44252
2 EX-4.1 abio-ex41_9.htm EX-4.1 141863
3 EX-5.1 abio-ex51_28.htm EX-5.1 18681
4 EX-10.1 abio-ex101_205.htm EX-10.1 345291
5 EX-99.1 abio-ex991_117.htm EX-99.1 11300
6 EX-99.2 abio-ex992_116.htm EX-99.2 349747
7 GRAPHIC gxjftv44ydxx000001.jpg GRAPHIC 28720
8 GRAPHIC gvvpykh33k1b000001.jpg GRAPHIC 20861
  Complete submission text file 0001564590-20-028159.txt   981045
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 20939098
SIC: 2835 In Vitro & In Vivo Diagnostic Substances